The Federal Trade Commission says Abbott Laboratories (ABT) can proceed with its proposed $25 billion acquisition of St. Jude Medical (STJ) . As a result of the green light, Abbott will sell two medical device units to Tokyo-based Terumo for $1.2 billion. The merger of Abbot and St. Jude was cleared by European antitrust regulators back in November, provided that U.S. regulators were on board with the transaction.

More from Video

If You Want to Invest in Artificial Intelligence, Here's the One Stock to Buy

If You Want to Invest in Artificial Intelligence, Here's the One Stock to Buy

Economist Perspective: Brexit Endgame in Sight?

Economist Perspective: Brexit Endgame in Sight?

Smaller Cap Stocks Could Make Great Stocking Stuffers Ahead of 2019

Smaller Cap Stocks Could Make Great Stocking Stuffers Ahead of 2019

5 Highly Anticipated Tech IPOs to Watch in 2019

5 Highly Anticipated Tech IPOs to Watch in 2019

Trading Strategies: How to Play the Federal Reserve's Decision Next Week

Trading Strategies: How to Play the Federal Reserve's Decision Next Week